Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 11/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038611 | 0.84 | CSF1R (0.38) | CSF1RLPLLIPGEGFRAAK1 | |
| SCHEMBL529553 | 0.84 | MEN1 (0.39) | CSF1RLPLLIPGEGFRAAK1 | |
| SCHEMBL30124524 | 0.84 | GAA (0.36) | CSF1RLPLLIPGEGFRAAK1 | |
| SCHEMBL4789211 | 0.84 | LPL (0.42) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL24309439 | 0.83 | AAK1 (0.35) | LPLLIPGAAK1CA1CA2 | |
| SCHEMBL3239432 | 0.81 | LPL (0.38) | CSF1RLPLLIPGAAK1SNCA | |
| SCHEMBL30159215 | 0.80 | PDE4A (0.37) | CSF1RLPLLIPGEGFRAAK1 | |
| SCHEMBL23797605 | 0.80 | CSF1R (0.36) | CSF1RLPLLIPGEGFRAAK1 | |
| SCHEMBL30207484 | 0.80 | CSF1R (0.36) | CSF1RLPLLIPGEGFRAAK1 | |
| SCHEMBL858457 | 0.80 | CSF1R (0.45) | CSF1RLPLLIPGEGFRAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | CSF1R 2312/4885LPL 3249/4885LIPG 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.